Precision Biosciences (DTIL) Non Operating Income (2018 - 2026)
Precision Biosciences (DTIL) reported Non Operating Income of -$9.4 million for Q1 2026, down 705.43% year-over-year from $1.5 million in Q1 2025, and down 238.96% on a QoQ basis from $6.7 million in Q4 2025.
Precision Biosciences (DTIL) has 9 years of Non Operating Income data on file, last reported at -$9.4 million in Q1 2026.
- Quarterly Non Operating Income fell 705.43% year-over-year to -$9.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.4 million (down 124.32% YoY) and the FY2025 annual result came in at $5.5 million, down 83.38% from the prior year.
- Non Operating Income slipped to -$9.4 million in Q1 2026 per DTIL's latest filing, from $6.7 million in the prior quarter.
- Across five years, Non Operating Income topped out at $12.8 million in Q1 2024 and bottomed at -$9.4 million in Q1 2026.
- The 5-year median for Non Operating Income is $96000.0 (2023), against an average of $1.2 million.
- The widest annual swing landed in 2022, when Non Operating Income sank 6270.83%; it then jumped 8861.46% in 2024.
- Tracing DTIL's Non Operating Income over 5 years: stood at -$7.3 million in 2022, then jumped by 119.9% to $1.5 million in 2023, then jumped by 387.71% to $7.1 million in 2024, then decreased by 5.08% to $6.7 million in 2025, then sank by 238.96% to -$9.4 million in 2026.
- Per Business Quant, the three latest DTIL Non Operating Income figures stand at -$9.4 million (Q1 2026), $6.7 million (Q4 2025), and -$1.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Precision Biosciences | 171.70 Mn | 70.52 Mn | - | -9.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.37 Mn |
| Dec 31, 2025 | 6.74 Mn |
| Sep 30, 2025 | -1.11 Mn |
| Jun 30, 2025 | -1.64 Mn |
| Mar 31, 2025 | 1.55 Mn |
| Dec 31, 2024 | 7.10 Mn |
| Sep 30, 2024 | 4.85 Mn |
| Jun 30, 2024 | 8.60 Mn |
| Mar 31, 2024 | 12.78 Mn |
| Dec 31, 2023 | 1.46 Mn |
| Sep 30, 2023 | 253,000.00 |
| Jun 30, 2023 | 96,000.00 |
| Mar 31, 2023 | -596,000.00 |
| Dec 31, 2022 | -7.32 Mn |
| Sep 30, 2022 | -1.02 Mn |
| Jun 30, 2022 | -1.48 Mn |
| Mar 31, 2022 | -833,000.00 |
| Dec 31, 2021 | 8.43 Mn |
| Sep 30, 2021 | 263,000.00 |
| Jun 30, 2021 | 24,000.00 |
| Mar 31, 2021 | 53,000.00 |
| Dec 31, 2020 | 27,000.00 |
| Sep 30, 2020 | 28,000.00 |
| Jun 30, 2020 | 107,000.00 |
| Mar 31, 2020 | 660,000.00 |
| Dec 31, 2019 | 945,000.00 |
| Sep 30, 2019 | 1.24 Mn |
| Jun 30, 2019 | 4.44 Mn |
| Mar 31, 2019 | -12.29 Mn |
| Dec 31, 2018 | 662,000.00 |
| Sep 30, 2018 | 691,000.00 |
| Jun 30, 2018 | 299,000.00 |
| Mar 31, 2018 | 223,000.00 |